Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: A systematic review of efficacy and tolerability

Current Psychiatry Reports

Volumn 15, Issue 5, 2013, Pages

  Linton, David ^a,b   Barr, Alasdair M ^a,b   Honer, William G ^a,b   Procyshyn, Ric M ^a,b  

^a BC Mental Health and Addictions Research Institute   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ADHD; Adolescents; Antipsychotic agents; Attentiondeficit hyperactivity disorder; CD; Central nervous system stimulants; Children; Combination therapy; Conduct disorder; DBD; Disruptive behavior disorders; Guidelines; ODD; Oppositional defiant disorder; Psychiatry

Indexed keywords

METHYLPHENIDATE; NEUROLEPTIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE;

AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BODY MASS; COMORBIDITY; CONDUCT DISORDER; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 84875290063     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0355-6     Document Type: Review

References (47)

1. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679.
2. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry. 2003;42:132-44. (Pubitemid 39610593)
3. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21:537-43.
4. Rani F, Murray ML, Byrne PJ, Wong ICK. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121:1002-9.
5. Barr AM, Panenka WJ, Honer WG, Khara S, Procyshyn RM. Excessive antipsychotic dosing in a Canadian outpatient population. Psychiatr Serv. 2011;62:682-3.
6. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry. 2010;71:566-73.
7. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158:753-9. (Pubitemid 39025073)
8. Koelch M, Prestel A, Singer H, Keller F, Fegert JM, Schlack R, et al. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol. 2009;19:765-70.
9. Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012;57:52-8.
10. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49:1001-10.
11. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affair. 2009;28:770-81.
12. Matone M, Localio R, Huang Y-S, dosReis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of US Medicaid-enrolled children. Health Serv Res. 2012;47:1836-60.
13. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642-57. (Pubitemid 43833097)
14. Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353-364.
15. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72:655-70.
16. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni Jr RH. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253-61. (Pubitemid 38338146)
17. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600-20.
18. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-46. (Pubitemid 34832715)
19. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-36. (Pubitemid 38338050)
20. Loy JH, Merry SN, Hetrick SE, Stasiak K: Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database of Systematic Reviews. 2012, Issue 9. Art. No.: CD008559. doi:10.1002/14651858. CD008559.pub2.
21. Otasowie J, Duffy R, Freeman J, Hollis C. Antipsychotic prescribing practice among child psychiatrists and community paediatricians. Psychiatrist. 2010;34:126-9.
22. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci. 2007;32:331-8. (Pubitemid 47492758)
23. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci. 2010;31:484-97.
24. Barr AM, Honer WG, Johnson JL, Wu TK, Procyshyn RM. A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms. J Clin Psychopharmacol. 2011;30:741-3.
25. Leung JYT, Barr AM, Procyshyn RM, Honer WG, Pang CCY. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135:113-22.
26. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-45. (Pubitemid 38068023)
27. Patel NC, Hariparsad M, Matias-Akthar M, Sorter MT, Barzman DH, Morrison JA, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007;17:303-11. (Pubitemid 47067954)
28. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004;14:350-8. (Pubitemid 39473121)
29. Correll CU, Kratochvil CJ. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9-20.
30. Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont). 2010;7:18.
31. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Mol Psychiatry. 2005;10:79-104. (Pubitemid 40139590)
32. Castellanos FX. Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr (Phila). 1997;36:381-93. (Pubitemid 27297591)
33. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3:386-96. (Pubitemid 28442411)
34. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1-24.
35. Kewley GD. Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry. 1999;38:1327-8.
36. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11-28. (Pubitemid 37495027)
37. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003;42:145-61. (Pubitemid 39610594)
38. Scotto Roasato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PS. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics. 2012;129:1577-86.
39. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:558-65. (Pubitemid 46642572)
40. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17:1-9. (Pubitemid 46452077)
41. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/ absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243-54. (Pubitemid 38988790)
42. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatmentresistant adolescents with comorbid ADHD, conduct/oppositionaldefiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17:334-47. (Pubitemid 47067957)
43. Gittelman-Klein R, Klein DF, Katz S, Saraf K, Pollack E. Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. Arch Gen Psychiatry. 1976;33:1217.
44. Weizman A, Weitz R, Szekely GA, Tyano SAM, Belmaker RH. Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1984;23:295-8. (Pubitemid 14123751)
45. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19:563-73.
46. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19:101-9.
47. Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde LA. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19:553-61.